Amarin | AMRN - Pre Tax Profit

Stock Price
13.98
Daily Change
-0.15 -1.03%
Monthly
-7.27%
Yearly
28.94%
Q1 Forecast
15.11

Amarin reported $-8.12M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amarin USD -8.12M 5.34M Sep/2025
AstraZeneca USD 3.24B 117M Sep/2025
BioCryst Pharmaceuticals USD -86.95M 73.5M Dec/2024
DBV Technologies USD -33.16M 8.6M Sep/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Nektar Therapeutics USD -37.05M 15.27M Sep/2024
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 4.2B 335M Sep/2025